Impact Of Immunotherapy On Vestibular Function, The Mayo Clinic Arizona Experience

Overview

About this study

This study evaluates the impact of immunotherapy on balance in patients receiving immunotherapy as part of their standard of care.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* At least 18 years of age at screening
* Patients who will be initiating single agent immunotherapy with pembrolizumab, cemiplimab, nivolumab, atezolizumab, or dual therapy with (Ipilimumab/Nivolumab or Nivolumab/Relatlimab)

Exclusion Criteria:

* Concurrent chemotherapy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Carrlene Donald

Open for enrollment

Contact information:

Carrlene Donald

(480) 342-4200

donald.carrlene@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20591172

Mayo Clinic Footer